RGDXQ (Response Genetics) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2015)


What is Response Genetics ROE % Adjusted to Book Value?

Response Genetics RGDXQ -98.00% ROE % Adjusted to Book Value is 0.00% as of Dec. 2015.

Response Genetics's ROE % for the quarter that ended in Dec. 2015 was 0.00%. Response Genetics's PB Ratio for the quarter that ended in Dec. 2015 was N/A. Response Genetics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2015 was N/A.

Response Genetics ROE % Adjusted to Book Value Related Terms

Response Genetics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Response Genetics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics ROE % Adjusted to Book Value Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -60.89 -229.36 0.00

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.28 -31.51 -386.31 0.00 0.00

RGDXQ vs PSID, GBSN, ETAH: ROE % Adjusted to Book Value Comparison

For the Diagnostics & Research subindustry, Response Genetics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Response Genetics ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Response Genetics's ROE % Adjusted to Book Value falls into.


Response Genetics ROE % Adjusted to Book Value Calculation

Response Genetics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2015 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-59.74% / N/A
=N/A

Response Genetics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2015 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Response Genetics (RGDXQ) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2015. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Response Genetics and its competitors.
Is Response Genetics' ROE % Adjusted to Book Value too high?
Response Genetics' current ROE % Adjusted to Book Value is 0.00%.
How does Response Genetics' ROE % Adjusted to Book Value compare to PSID and GBSN?
Response Genetics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Response Genetics and its competitors. Response Genetics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.